Peptide
Thymosin alpha-1
Thymalfasin (Tα1)
A 28-amino-acid peptide first isolated from the thymus gland. Approved in more than 30 countries outside the US for hepatitis B, hepatitis C, and adjunct cancer therapy. Never FDA-approved in the United States.
Summary Can thymosin alpha-1 slow aging or strengthen the immune system? Show / hide ↓
Thymosin alpha-1 is a small chain of 28 amino acids, the building blocks of proteins, that affects the immune system. It is approved in more than 30 countries for hepatitis B, hepatitis C, and use alongside some cancer treatments, but it has never been approved by the FDA in the United States. Studies in liver disease, infections, and sepsis include randomized controlled trials, meaning people were assigned treatments by chance, but results vary by condition. It may help adjust immune activity, including the work of cells that coordinate immune responses, but this does not prove it slows aging. There is no direct evidence that it extends lifespan or improves health in otherwise healthy adults.
What this means for you: Thymosin alpha-1 has established medical use in some countries, but its value for longevity is unproven. It is not enough evidence to use it as an anti-aging treatment.
weak evidenceThymosin alpha-1 is one of the few peptides with meaningful regulatory approvals outside the US. In Italy and China it is a standard adjunct for hepatitis B and hepatitis C, and it is used off-label as an immune support in cancer and sepsis. In the US it exists in a legal gray zone: never approved, occasionally compounded, and periodically restricted.
Mechanically, Tα1 modulates immune cells. It appears to enhance Th1-type responses, promote dendritic cell maturation, and normalize dysregulated cytokine patterns. This is why it has been tried in so many disparate conditions — chronic viral infection, sepsis, cancer immunotherapy, and post-viral fatigue. During COVID-19, several Italian and Chinese trials examined thymosin alpha-1 for severe cases with mixed results; a 2020 Chinese cohort study suggested a mortality benefit that later meta-analyses treated cautiously.
For longevity, the argument is that immune aging (immunosenescence) is a hallmark of biological aging, and Tα1 might restore some of what a shrinking thymus stops producing. There is no direct evidence that Tα1 extends healthspan or lifespan in adults without an underlying condition. What there is: decades of use in liver disease and infection with an acceptable safety profile, and a mechanism that is at least tangentially related to age-related immune decline.
Compounding-pharmacy availability in the US has been contentious. The FDA has been narrowing what peptides can be legally compounded, and Tα1 has moved on and off the acceptable list.
Thymosin Alpha-1 has the largest human RCT of any peptide on this list, a 1,106-patient sepsis trial that found no overall mortality benefit, even though it is already approved in over 35 countries under the brand name Zadaxin.
Verified 2026-08-06. We update this section as PCAC decisions, ClinicalTrials.gov entries, and new peer-reviewed studies land.
FDA / PCAC (July 2026)
Not reviewed at July 2026 PCAC meeting. The July 2026 review covered BPC-157, KPV, TB-500, MOTS-c, Epitalon, Semax, and Emideltide (DSIP); Thymosin Alpha-1 was not among them (https://validusbio.com/learn/pcac-2026-peptide-vote-results/).
US status
Not FDA approved in the US for any indication; sold as a research-use compound domestically. FDA maintains a separate bulk-drug-substance nomination record for thymosin alpha-1 outside the July 2026 seven-peptide review (https://www.fda.gov/media/183892/download).
EU status
Not authorised for human use in EU as of 2026; approved as Zadaxin (thymalfasin) in over 35 countries worldwide, primarily in Asia, for hepatitis B/C and as an immune adjuvant, though not through EMA centralized approval.
Best-supported claim
Thymosin Alpha-1 is the only peptide in this set with a completed, adequately powered, multicentre phase 3 RCT: the 1,089-patient TESTS trial published in BMJ in 2025 confirmed a good safety profile and found no overall mortality benefit in sepsis, though prespecified subgroup analysis suggested possible benefit in patients aged 60 and older (https://www.bmj.com/content/388/bmj-2024-082583). A 2025 systematic review and meta-analysis of 11 RCTs covering 1,927 sepsis patients found an overall 28-day mortality reduction (OR 0.73, P=0.003), but the effect disappeared in the five higher-quality, multicenter trials (OR 0.82, P=0.09), and trial sequential analysis found the evidence base still insufficient to confirm efficacy (https://pmc.ncbi.nlm.nih.gov/articles/PMC12440967/).
Not supported by the evidence base
Longevity and immune-support vendors market Thymosin Alpha-1 broadly as an immune booster for healthy people and a cancer-fighting agent, citing its approved status abroad as if that constituted general efficacy proof (https://frenchpeptides.com/en/guides/thymosin-alpha-1-pharmacology-research-2026/). The largest and most rigorous RCT to date (TESTS, n=1089) found no significant mortality benefit in critically ill sepsis patients, its most heavily studied indication. Applying "immune-boosting" claims to healthy people who are not septic, immunocompromised, or undergoing chemotherapy has no controlled trial support at all.
Typical usage
1.6 mg subcutaneous injection every 12 hours for 7 days in the sepsis RCT protocol; in approved international use (Zadaxin) for chronic hepatitis, dosing is typically 1.6 mg subcutaneous twice weekly for extended courses of several months.
Safety
The TESTS trial (n=1089) found a favorable safety profile with similar adverse-event rates between thymosin alpha-1 (66.4%) and placebo (67.6%), and no unexpected serious adverse events related to the drug (https://www.bmj.com/content/388/bmj-2024-082583). As an immune modulator, it requires monitoring when combined with checkpoint inhibitors or other immunotherapies in cancer treatment. People with autoimmune disease should use it only under medical supervision given its immune-activating mechanism. It is not FDA-characterized under the July 2026 PCAC framework, so US compounding-specific risk assessment is incomplete (https://www.fda.gov/media/183892/download).
Interactions worth flagging
- Requires monitoring when combined with PD-1/PD-L1 checkpoint inhibitors in cancer immunotherapy protocols
- Theoretical interaction with other immunosuppressive or immunomodulating drugs
- No significant interaction signal identified with standard Surviving Sepsis Campaign background therapy in the TESTS trial
Three recent studies to know
-
The efficacy and safety of thymosin alpha1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
No significant reduction in 28-day mortality with thymosin alpha-1 versus placebo in adults with sepsis; favorable safety profile confirmed.
Read study → -
Efficacy of thymosin alpha1 for sepsis: a systematic review and meta-analysis
Pooled analysis of 11 RCTs found an overall mortality benefit that disappeared in higher-quality multicenter trials; trial sequential analysis found evidence still insufficient to confirm efficacy.
Read study → -
Thymosin Alpha-1 (Ta1) Related Bulk Drug Substances
FDA maintains a separate bulk drug substance nomination record for thymosin alpha-1, distinct from the July 2026 seven-peptide PCAC review.
Read study →
Further reading
Curated external sources for a deeper dive. External links open in a new tab.